To investigate the synergistic antitumor effects of murine IL-18 and CD/5FC gene therapy on mice bearing liver cancer.

To construct human c-fms antisense eukaryotic expressing vector that would express in human hepatoma cells efficiently and specifically and to observe its affection on biological behavior of hepatoma cells.

To observe the roles of c-myc gene amplification, MTS1/p16 gene alternation, and HBV infection in the pathogenesis and progression of hepatocellular carcinoma (HCC).

To evaluate the activity in vivo of 3 phosphorothioate antisense oligonucleotides, HCV363, HCV279 and HCV349 using nude mice xenograft models based on the establishment of HCV 5' NCR transgenic cellular model (HepG2.9706).

To define the relationship between Ph chromosome and BCR/ABL mRNA expression in chronic myeloid leukemia (CML) patients, and compare cytogenetic analysis and PCR method.

To evaluate the value of expression of WT1 gene in predicting the prognosis of leukemia patients, and explore the relationship between WT1 gene expression and multidrug resistance and cell apoptosis.

To determine the incidence of TEL-AML1 fusion gene and its role in clinical diagnosis and prognosis of childhood B-lineage acute lymphoblastic leukemia (B-ALL), and to compare the two techniques: nested RT-PCR and dual-color fluorescence in situ hybridization (FISH).

To probe the effect of c-erbB-2 specific ribozyme to the malignant phenotype of gastric cancer.

To explore the suppressive effects of a murine genomic p53 minigene containing an Arg-->Leu substitution at its encoding amino acid 172 on biological behaviors of human carcinoma cell and evaluate its potential application in cancer gene therapy.

To study the genomic abnormality underlying the blast crisis of chronic myeloid leukemia(CML).

To investigate the mutational features of adenomatous polyposis coli (APC) gene and their possible arising mechanism in colorectal tumors.

In order to locate the deletion areas probably harboring tumor suppressor genes on chromosome 14 and provide clues for discovering novel tumor suppressor genes.

To identify genetic alteration in primary sporadic nasopharyngeal carcinoma(NPC) in Hunan.

To investigate the frequency of HER-2 oncogene amplification in primary hepatocellular carcinoma (HCCs) and its relationships with clinicopathological parameters and prognosis, 42 surgical samples from patients with primary HCCs were detected for their HER-2 oncogene amplification by dual FISH technique, and then the correlations between HER-2 amplification and clinicopathological characteristics and prognosis were analyzed statistically. HER-2 oncogene amplification was detected in 9 of 42 (21.4%) primary HCCs, including 4 (9.5%) cases with high copy (HC) and 5 (11.9%) ones with low copy (LC). HER-2 amplification was associated significantly with postoperative survival time of HCC patients examined (P = 0.046) and the presence of HER-2 gene amplification showed a trend toward a correlation with tumor size (P = 0.085), but wasn't relative to sex, age, AFP level, HBV infection, postoperative relapse and clinical staging of HCC patients tested (P > 0.05). On the other hand, gain of the HER-2 oncogene copy was examined in 31 of 42(73.8%) primary HCCs, consisting of 9 (21.4%) cases with HER-2 amplification and 22(52.4%) ones with aneusomy 17/polysomy 17. There weren't significant relationships between gain of HER-2 oncogene copy and, HCC patient's sex, tumor size, clinical staging, postoperative relapse and survival time (P > 0.05), but gain of HER-2 oncogene copy correlated significantly to patients' age, AFP level and HBV infection (P < 0.05). The study indicated that there were a lower frequency of HER-2 oncogene amplification and a higher frequency of aneusomy 17/polysomy 17 in primary HCCs and that HER-2 oncogene amplification activation might be involved in the development and progression of a subset of HCCs, and seemed to be a valuably independent prognosis factor predicting postoperative poorer survival for patients with HCC.

To explore the expression of human telomerase reverse transcriptase (HTERT) and its relationship with tumor suppressor gene p53.

To determine the expression of ras, p53 and proliferating cell nuclear antigen (PCNA) in squamous cell carcinoma(SCC), inverting papilloma(IP), inflammatory mucosa(IM) of maxillary sinus and analyze the correlation between their expression and the clinicopathological characters and prognosis of SCC of maxillary sinus(SCCMS).

To study the RB1 gene in squamous cell carcinoma of larynx(ISCC) and to find clue for discovering and locating new suppressor gene.

To investigate the expression of bcl-2 gene and cell apoptosis and cell cycle in bone marrow of chronic myelogenous leukemia (CML).